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ABSTRACT: Chronic obstructive pulmonary disease (COPD) is predicted to become the third
most common cause of death and disability worldwide by 2020.
The prevalence of COPD defined by the lower limit of normal was estimated using high-quality
spirometry in surveys of 14 populations aged o40 yrs. The strength and consistency of
associations were assessed using random effects meta-analysis.
Pack-years of smoking were associated with risk of COPD at each site. After adjusting for this
effect, we still observed significant associations of COPD risk with age (OR 1.52 for a 10 yr age
difference, 95% CI 1.35–1.71), body mass index in obese compared with normal weight (OR 0.50,
95% CI 0.37–0.67), level of education completed (OR 0.76, 95% CI 0.67–0.87), hospitalisation with
a respiratory problem before age 10 yrs (OR 2.35, 95% CI 1.42–3.91), passive cigarette smoke
exposure (OR 1.24, 95% CI 1.05–1.47), tuberculosis (OR 1.78, 95%CI 1.17–2.72) and a family
history of COPD (OR 1.50, 95% CI 1.19–1.90).
Although smoking is the most important risk factor for COPD, other risk factors are also
important. More research is required to elucidate relevant risk factors in low- and middle-income
countries where the greatest impact of COPD will occur.
KEYWORDS: Age, chronic obstructive pulmonary disease, early life, risk factor, smoking,
tuberculosis
C
hronic obstructive pulmonary disease
(COPD) is defined as airway obstruction
that does not significantly decrease with
bronchodilators. It is operationally defined as a
post-bronchodilator forced expiratory volume in
1 s (FEV1)/forced vital capacity (FVC) ratio of
,70% [1], although it has been increasingly
recognised that this ratio should be normalised
for age. In this article we have used the lower
limit of normal for the definition [2, 3].
The impact of COPD is predicted to increase
worldwide [4]. These predictions are largely driven
by current estimates of mortality and prevalence,
and by predicted changes in the age structure and
smoking habits of the world’s population, espe-
cially in low- and middle-income countries. Data
from the Burden of Obstructive Lung Disease
(BOLD) study in Iceland and Norway show that
COPD accounts for 0.7–1.2% of the healthcare
budget, largely driven by the costs of exacerbations,
and that prevalence is likely to rise over the next
10–15 yrs [5].
The strongest risk factor for COPD and an acce-
lerated decline in adult lung function is cigarette
smoking, and smoking cessation is known to slow
the rate of decline of lung function [6–8]. However,
cigarette smoking alone does not explain the dis-
tribution of COPD, even in economically pros-
perous regions [9].
Other factors that increase the burden of inhaled
particulates and are associated with increased
oxidative stress in the lung, including outdoor
and indoor air pollution, and occupation [10, 11],
are also likely to increase the risk of COPD. In
addition, deaths from COPD are more strongly
associated with poor social conditions than
deaths from carcinoma of the bronchus, another
smoking-related disease [12]. Impaired adult
lung function has also been associated with
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c
childhood poverty [13], and more specifically with two
correlates of childhood poverty: low birthweight and lower
respiratory tract infections in infancy [14].
The BOLD programme is an international collaboration to
assess the prevalence and risk factors for COPD. This article
summarises the associations between spirometrically defined
COPD and its main risk factors.
METHODS
The design and rationale for the BOLD study, the character-
istics of samples and the prevalence of COPD in 12 sites have
been reported elsewhere [15, 16].
Lung function, including FEV1, forced expiratory volume in 6 s
(FEV6) and FVC, was measured using the ndd EasyOne
Spirometer (ndd Medizintechnik AG, Zurich, Switzerland), before
and 15 min after inhaled salbutamol (200 mg) by metered dose
inhaler with spacer. Spirograms were reviewed by the BOLD
Pulmonary Function Reading Centre, and assigned a quality score
based on acceptability and reproducibility criteria from the
American Thoracic Society (ATS) and European Respiratory
Society [17]. Spirometry technicians at BOLD sites were certified
before data collection, received regular feedback on quality and
were required to maintain a pre-specified quality standard.
Outcome measures were the following. 1) A modification of
the Global Initiative for Chronic Obstructive Lung Disease
(GOLD) stage I or higher COPD, defined as a post-broncho-
dilator FEV1/FVC ratio below the lower limit of normal for age
and sex, based on reference equations for ‘‘Caucasians’’
derived from the third US National Health and Nutrition
Examination Survey (NHANES) [18]. 2) The continuous post-
bronchodilator FEV1/FVC ratio, expressed as a percentage.
Prevalence of modified GOLD stage I or higher was estimated
at each centre for males and females overall, and in subgroups
defined by age and smoking, allowing for sampling weights
and stratification or clustering in the sampling at each site.
Information on respiratory symptoms, health status and expo-
sure to risk factors was obtained using face-to-face interviews
conducted in the subject’s native language by trained and
certified staff. Questions about cigarette smoking were derived
from the 1978 ATS Epidemiology Standardisation Project [19],
and other sections of the interview were derived from the Euro-
pean Community Respiratory Health Study [20], the Consilio
Nazionale de Ricerche (CNR) study [21] and the Obstructive
Lung Disease in Northern Sweden (OLIN) study [22].
Risk factors investigated were: age; sex; body mass index (BMI;
categorised as normal/underweight ,25 kg?m-2; overweight
25–30 kg?m-2 or obese .30 kg?m-2), education (categorised as
none, primary or middle school, secondary school, technical/
vocational college or university); father’s education (cate-
gorised similarly); hospitalisation for breathing problems
before age 10 yrs; pack-years of smoking (number of cigarettes
smoked per day divided by 20 and multiplied by years of
smoking); current smoking; passive smoking (somebody else
smoking in the subject’s home in the last 2 weeks); doctor-
diagnosed tuberculosis (ever); family history of COPD (doctor
ever-diagnosed mother, father, sister or brother with emphy-
sema, chronic bronchitis or COPD); years working in dusty
jobs; regular exposure to dust in present job; regular exposure
to fumes in current job; years of heating home with biomass
fuel (coal, coke, peat, wood, crop residue or dung); and
equivalent years of continuous exposure to cooking fires using
biomass fuel (calculated by multiplying number of years over
which subject was exposed by number of hours exposure per
day divided by 24). Both for heating and cooking, exposures to
coal, coke or peat fires, and to wood, crop residue or dung fires
were recorded separately on the questionnaire. However,
respondents frequently reported identical durations of exposure
to each, and the distribution of time exposed in this case was
similar to that of respondents who used just one type of fire. We
therefore used the maximum of the two durations, rather than
adding them together.
Effects of subject’s and father’s education were modelled as
linear trends across the categories. Father’s education was
reported as unknown for around a quarter of participants: this
was coded as no education to allow the trend effect to be
estimated, and the independent effect of unknown versus no
education was estimated as a separate covariate. The other risk
factors that could be reported on the questionnaire as unknown
were subject’s own education, and hospitalisation for breathing
problems before age 10 yrs: in the few cases where this
occurred, these values were treated as missing.
We attempted to include all risk factors in the regression
analyses of every centre, but in the analysis of COPD there
were occasions where the exposed subgroup at a centre was
small and did not include any cases of COPD. This meant that
the subgroup had to be excluded from the analysis, and the
effect of the factor was not estimated for this centre.
Age, pack-years of smoking, years working in dusty jobs, years
exposed to biomass heating and years exposed to biomass
cooking were modelled as continuous variables, but to allow
for possible nonlinear effects, we first considered a model in
each centre in which these variables had quadratic effects, and
looked at the results of meta-analysing each quadratic term. In
the case of age, years working in dusty jobs and years exposed
to biomass cooking, nonlinear effects were homogeneous and
nonsignificant and we, therefore, used linear effects of these
variables in the final regression model. In the case of pack-
years of smoking, nonlinear effects were heterogeneous and
significant overall and we, therefore, retained a quadratic effect
of this variable in the final regression model. Models that
included quadratic effects of years exposed to biomass heating
and models that divided years exposed to biomass heating into
three categories did not fit the data noticeably better at any
centre than models that used a linear effect of years exposed
to biomass heating, according to the Hosmer–Lemeshow
goodness-of-fit tests [23]. We decided, for simplicity, to model
years exposed to biomass heating as a linear effect.
We tested for interactions between sex and all other risk factors
in each centre. Of those interactions that could be estimated,
none were statistically significant using a Simes procedure to
allow for the multiple testing [24]. We did not, therefore,
include any interactions in the final regression models.
Because smoking was known a priori to be an important risk
factor for COPD, and in order to adjust for its effects as
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accurately as possible, we preferred to model pack-years of
smoking as a continuous variable with a nonlinear effect.
We used multiple logistic regression to estimate the effects of
risk factors on COPD, and multiple linear regression to analyse
the FEV1/FVC ratio. Participants with unacceptable or un-
reproducible post-bronchodilator spirometry, as well as those
who had had part of a lung removed, were excluded. Effects of
all risk factors were mutually adjusted, and estimated allowing
for sampling weights and stratification or clustering in the
sampling at each site. Regression models were fitted separately
for each site, and results for each risk factor were pooled across
sites using random effects meta-analysis [25]. Heterogeneity
was summarised using the I2 statistic [26]. Where a site did not
collect information on biomass exposure, these risk factors
were not included in the model for that site. p-values ,0.05 are
referred to as significant.
All analyses were performed using Stata 10 (Stata Corp.,
College Station, TX, USA).
Ethical approval was obtained by each site from the local ethics
committee, and written informed consent was obtained from
every subject.
RESULTS
14 sites had completed data collection by December 31, 2007.
Sites were asked to provide at least 600 participants, and the
number ranged from 563 to 1,349. Response rates varied from
.70% at four sites to ,50% in three [3].
Figure 1 shows some of the characteristics of males and
females at different sites. In this figure, the sites have been
ordered according to the proportion educated to college or
university level. Proportions educated to college or university
level ranged from 4.9% in males and 2.0% in females (Adana,
Turkey) to 78.1% in males and 73.4% in females (Vancouver,
Canada). Although this is a crude measure of socioeconomic
status, it gives a useful ordering of sites because it is virtually
independent of sex. Arranging the data in this way also helps
to illustrate ecological associations. Sites with a higher level
of education tended to have lower proportions of passive
smokers, higher proportions hospitalised for breathing
problems before the age of 10 yrs, and lower proportions
exposed to biomass fires for cooking. Among males, at least,
there was a tendency to have lower proportions of current
and ever-smokers.
Tuberculosis was relatively commonly diagnosed in Cape
Town, South Africa (19.2% in males and 12.0% in females) and
Manila, Phillippines (14.3% in males and 8.0% in females),
while a family history of COPD was notably prevalent in
Lexington, KY, USA (35.0% in males and 44.8% in females).
Current exposure to dust at work was most common in Manila
(47.5% in males and 21.5% in females) as was current exposure
to fumes at work (40.1% in males and 18.0% in females).
Exposure to biomass fires for heating was widespread in
Adana and Krakow, Poland, and was also common in
Lexington and London, UK.
The prevalence of COPD (modified stage I) in males ranged
from 7% in Sydney, Australia, to 23% in Cape Town (table 1).
In females it ranged from 4% (Manila) to 21% (Salzburg,
Austria).
We observed a significant effect of pack-years of smoking on the
risk of COPD at each site (p,0.005 in each case). In pooled meta-
analyses of multivariate models that also adjusted for pack-
years of cigarette smoking, we observed significant associations
between the prevalence of COPD and each of BMI, level of
education, hospitalisation with a respiratory illness before the
age of 10 yrs, passive cigarette smoke exposure and a family
history of COPD (table 2). We found qualitatively similar results
when we used the continuous FEV1/FVC ratio as our outcome.
Both current smoking and a history of tuberculosis were
associated with increased risk of COPD in the logistic regression
analyses, but were not significantly associated with the
continuous FEV1/FVC ratio measure. The opposite pattern
was observed for years worked in a dusty job. Mean FEV1/FVC
declined significantly with increasing age and the ratio was
higher for females than for males. Increasing age was also
significantly associated with increased risk of the modified
GOLD stage I definition of COPD.
Table 3 provides the same information as table 2, but defines
COPD stage I by the GOLD criterion of an FEV1/FVC ,0.7 at
all ages. As expected, the coefficients for age and sex are
different from those in table 2. All other coefficients are
substantively the same. Although the significance test gives a
different result for years of exposure to dust, the estimates are
not significantly different from each other.
Although the regression estimates in table 2 are pooled across
sites, we observed statistically significant heterogeneity across
sites in the effects of sex, age, BMI, hospitalisation before the
age of 10 yrs and current smoking on the binary COPD
outcome, and in the effects of BMI, current smoking and
tuberculosis on the continuous FEV1/FVC ratio. The corre-
sponding I2 statistics and heterogeneity tests are also presented
in figure 2. As an example, figure 2 shows the Forest plot for
passive smoking.
DISCUSSION
We have found significant associations between COPD and
smoking, environmental tobacco exposure, age, education,
tuberculosis, hospitalisation for respiratory illness before the
age of 10 yrs, a family history of COPD and the number of
years worked in dusty jobs.
We have used the ratio of FEV1 to FVC to define COPD. Unlike
the FEV1 and FVC individually, the ratio is not strongly related
to ethnicity [27–29] and hence is a suitable measure for
international comparisons. We used the lower limit of normal
of the FEV1/FVC ratio to define obstruction, rather than an
FEV1/FVC ratio ,0.70 as recommended by GOLD, since the
latter is prone to bias by age [2]. We have referred to our
measure as ‘‘modified’’ GOLD stage I COPD. This is to be
preferred to using the original GOLD stage II, which has the
same effect [3] as it uses only the FEV1/FVC ratio and does not
also include the FEV1.
Recently, it has been suggested that measuring the FEV6 would
be more reliable than measuring the FVC [30]. We have re-run
the analyses presented here using the FEV1/FEV6 ratio in place
of the FEV1/FVC ratio and found that the heterogeneity of the
risks estimated in different sites was reduced, particularly
when using the binary outcome. Apart from this, we observed
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for heating
Regular exposure to fumes
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in present job
Doctor ever-diagnosed
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Hospitalised for breathing
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Passive smoking (someone
else smoking in the subject’s
home in the last 2 weeks)
Current smoking
Ever smoked
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FIGURE 1. Characteristics of the populations studied at different sites (calculated using probability weights to allow for the sampling design at each site). COPD: chronic
obstructive pulmonary disease.
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only minor changes and we have kept to the more conven-
tional measurements (FEV1 and FEV1/FVC) in this report.
The major effects of smoking on COPD have been extensively
recorded over .40 yrs [31]. The measured association between
passive smoking and COPD is strong and consistent across the
sites, despite the crude assessment of exposure such as some-
body else smoking in the subject’s home in the last 2 weeks.
Such associations have been reported before [32]. The link
between passive smoking and COPD in Guangzhou, China has
also been highlighted before [33].
There are reasons to believe that females may be at different
risk from males because of differences in airway geometry,
pattern of deposition of particles in the airway and, perhaps,
hormonal differences [34]. However, dividing our samples
according to sex would have increased the frequency with
which small subgroups would have had to be excluded from
the analysis because they predicted outcome perfectly, thus
adversely affecting the accuracy of our estimates. We tested for
interactions between sex and other factors in each site: none
were statistically significant using a Simes procedure to allow
for multiple testing [24] and, in the absence of internal
evidence for differences between males and females, we chose
to combine the sexes. In the PLATINO study, the prevalence of
COPD was also similar between the sexes with the exception of
current smokers where GOLD stage tended to be more severe
among females. However, females reported more dyspnoea for
a given level of ventilatory impairment [35].
Prevalence of COPD increased with age, even though our
spirometric definition of COPD already takes account of the
age of the participants, as does pack-years of smoking, with
which it is strongly correlated. This most probably reflects the
cumulative effects of many other unmeasured risks, including
potentially those from air pollution [10], a poor diet [36, 37],
poor social conditions and infections. The extent to which this
association represents a cumulative effect across the age span
and to what extent it marks an effect from early life associated
with some birth cohorts is impossible to tell from these cross-
sectional data.
A higher level of education was strongly and significantly
associated with less disease. The effect did not show much
variation across the different sites, although details of the
educational system vary significantly. Educational level has
previously been associated inversely with COPD and with a
more rapid decline in lung function [38]. Education is inversely
TABLE 3 Pooled estimates of effects of risk factors on Global Initiative for Chronic Obstructive Lung Disease stage I or higher
chronic obstructive pulmonary disease (COPD)# adjusted for all risk factors in the regression model, including pack-
years of smoking
OR (95% CI) p-value I2 % p-value for heterogeneity
Female 0.75 (0.64–0.89) 0.001 30 0.11
Age (per 10-yr difference) 2.14 (1.98–2.31) ,0.001 41 0.042
BMI kg?m-2
,25 1.00
25–30 0.64 (0.51–0.79) ,0.001 58 0.002
.30 0.60 (0.47–0.76) ,0.001 53 0.006
Education" 0.81 (0.74–0.89) ,0.001 0 0.62
Hospitalisation for breathing problems
before age 10 yrs
2.11 (1.29–3.44) 0.003 61 0.001
Current smoking 1.34 (1.12–1.61) 0.002 30 0.11
Passive smoking+ 1.22 (1.06–1.41) 0.006 7 0.38
Doctor ever-diagnosed tuberculosis 1.72 (1.19–2.48) 0.004 56 0.003
Family history of COPD1 1.38 (1.17–1.63) ,0.001 0 0.75
Years working in dusty jobs per 10-yr
difference
1.08 (1.02–1.13) 0.003 1 0.44
Regular exposure to dust in present job 0.85 (0.66–1.11) 0.23 43 0.032
Regular exposure to fumes in present job 1.00 (0.79–1.26) 0.97 0 0.62
Years exposed to biomass fires per 10-yr
differencee
For heating 1.03 (0.97–1.10) 0.33 0 0.52
For cooking## 0.98 (0.70–1.37) 0.91 4 0.41
BMI: body mass index. #: stage I or higher COPD defined as forced expiratory volume in 1 s/forced vital capacity ratio ,0.7. ": effect per group, assuming a linear effect
over the four groups of highest level of education, as follows: none; primary (primary or middle school); secondary (secondary school); tertiary (technical/vocational
college or university). +: somebody else smoking in the subject’s home in the last 2 weeks. 1: doctor ever-diagnosed mother, father, sister or brother with emphysema,
chronic bronchitis or COPD. e: fires burning coal, coke, peat, wood, crop residue or dung. ##: years of equivalent continuous exposure are calculated by multiplying
number of years over which subject was exposed by number of hours of exposure per day divided by 24.
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associated with many other risk factors such as smoking and
occupation [39], which have been adjusted or partly adjusted
for in this analysis. It may also be associated with other risk
factors not included in this analysis, such as social conditions
early in life and diet.
The lower prevalence of COPD in those with high BMI is
similar to that reported by other studies [40–44]. In both a
larger Chinese study using the BOLD methodology [40] and in
the PLATINO study, which used substantially the same
methods [43], there was a continuous increase in COPD
prevalence as body mass increased, and the prevalence was
particularly high in those who were ‘‘underweight’’. In our
data, we are able to confirm the association with low body
mass but have too few underweight subjects to add reliable
information on this specific subgroup. LAMPRECHT et al. [44]
showed an increased risk in nonsmokers with low body mass,
but used less stringent methods to account for between-centre
variation in effects. Paradoxically, it has been noted that when
subjects give up smoking, the benefits to both FEV1 and FVC
are reduced if they also put on weight [45].
Hospitalisation for a respiratory illness before the age of 10 yrs,
another recorded marker of early childhood environment or
asthma, was also strongly associated with obstruction, though
the size of effect was not consistent across sites. In a cross-
sectional survey, this characteristic may be subject to marked
recall bias. Although there is longitudinal evidence that early
respiratory problems are associated with adult lung function
[46], this does not exclude differential recall. In addition,
hospitalisation in childhood does not have the same connota-
tion in every site. In this study, the highest percentage of
people answering positively to this question was in
Vancouver, Canada, where we would not expect the worst
respiratory health in early life. In the same way, the question
on first degree relatives with COPD could be subject to
selective recall. Because of the danger that we over-controlled
our model by including early childhood hospitalisation and
family history, we have checked whether excluding these
variables from the model alters any of the other conclusions
from the study: it does not.
A history of tuberculosis was strongly associated with the
binary definition of COPD in this study and the effect was
consistent across our sites. With the ratio of FEV1 to FVC as a
continuous outcome, the effect was much less consistent across
sites and was not significant. A similar association was
recorded previously in the PLATINO study [47]. While the
association between airflow obstruction and tuberculosis was
initially proposed .50 yrs ago, supporting data for this
hypothesis in the interim have been lacking. Whether the
obstruction is due to the pathological changes of tuberculosis
or to associated risks, such as smoking and exposure to
biomass fuel, is not fully resolved. However, the association is
still found in this analysis after controlling for some of these
risk factors.
In this article, we have looked only at more general markers of
industrial exposure, but these questions appear to be as
sensitive as some more elaborate methods [48]. Years worked
Overall (I2=0.0%, p=0.451)
Subtotal (I2=0.0%, p=0.909)
Subtotal (I2=20.5%, p=0.254)
Sweden
Australia
Germany
Norway
UK
Philippines
Canada
Poland
Iceland
South Africa
Austria
USA
Turkey
China
Countries with biomass data
Country
Countries without biomass data
1.24 (1.05–1.47)
1.21 (0.97–1.50)
1.50 (1.01–2.23)
1.77 (0.66–4.77)
1.09 (0.39–3.09)
1.42 (0.66–3.06)
1.96 (0.90–4.26)
1.95 (1.00–3.79)
0.85 (0.32–2.24)
1.43 (0.80–2.56)
1.03 (0.54–1.97)
0.94 (0.59–1.50)
1.08 (0.72–1.63)
0.79 (0.39–1.60)
1.09 (0.69–1.71)
3.12 (1.21–8.04)
ES (95%CI)
1.62 (0.89–2.96)
100.00
81.82
18.18
2.89
2.62
4.86
4.72
6.42
3.03
8.36
6.72
13.10
16.78
5.69
13.84
3.16
Weight %
7.82
0.5 1 2 5 100.20.1
FIGURE 2. Forest plot showing associations between passive cigarette smoke exposure and modified Global Initiative for Chronic Obstructive Lung Disease stage I or
higher chronic obstructive pulmonary disease. Note, weights are from random effects analysis. ES: effect size ; 95% CI: 95% confidence interval.
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in a dusty job were associated with a lower FEV1/FVC ratio,
although the effect was not significant when the less sensitive
binary outcome was used. In contrast, we observed possible
evidence of a healthy worker effect in those exposed to dust in
their current jobs. A similar effect in those currently exposed to
fumes was smaller and not significant.
We did not demonstrate any association between burning of
biomass or solid fuels and obstruction. The odds ratios were
consistently low and showed little variation across sites.
Although much of the interest in indoor pollution has focused
on the effects on children, there are reports of increased
obstruction particularly in females exposed to indoor pollution
from solid fuels. Odds ratios adjusted for age and smoking
have been estimated to be ,3 for exposure to solid fuels in the
home, with the effect being most clear in females [49]. In
addition, mitigation of such exposures may lead to improved
health [50]. In an extension of the BOLD study in China
(CESCOPD), using the same instruments as reported here,
ZHONG et al. [40] have estimated an adjusted odds ratio of 1.35
(95% CI 1.20–1.52), which is significantly greater than that
reported for Guangzhou in this analysis and significantly
lower than the odds ratios reported in an earlier meta-analysis
[49]. The reasons for these discrepancies are unclear. Analysis
of our Guangzhou data using the same model as in the paper
from China produced an odds ratio of 0.90, so we do not
believe it is due to differences in the methods used. The lack of
an effect does not seem to be ascribable to lack of use of such
fuels, as some sites reported substantial use and the lack of an
effect was universal. It is likely that the ventilation of the
houses and cooking areas was different, and there were
important differences in the biomass fuels used across sites
These findings caution against generalising the size of effects
of biomass and solid fuel use on lung health without more
information on how and which fuels are used and perhaps
when in the lifecycle there was exposure. This said, there is an
important possibility that some of the current conclusions on
COPD and biomass exposure are affected by publication bias.
In a recent review [51], there was a clear association between
the breadth of the confidence intervals of the effects and the
size of the effects, and the smallest confidence interval was
associated with an odds ratio of around 1.03, very similar to
the estimates given here [51].
Consistency across sites and strength of association are
suggestive of true causal associations, but are neither ne-
cessary nor provide sufficient evidence. Inconsistencies
across sites may be due to imprecise measurements and
unresolved confounding or effect modification. A lot of the
heterogeneity across sites was removed by using FEV1/FEV6
in place of FEV1/FVC. Three sites, Lexington, London and
Sydney, had low response rates. This is common in several
areas where there is either a low tolerance of surveys or
where there is a very mobile population. Low response rates
are not likely to have a large effect on estimated relative risks
and are more a problem for estimates of prevalence. None of
these three centres has a particular influence on the re-
gressions and none shows an obviously different pattern
from the other centres.
So far, the BOLD study has collected data largely in developed
market economies. Relatively little information has been
collected from low income countries and future research will
be focused more on the developing economies where the main
burden of the coming epidemic has been predicted. As
expected, the dominant risk identified was smoking. It is
increasingly emphasised that other factors are important and
some of these, including factors operating in infancy (or even
pre-natally), are difficult to assess in cross-sectional surveys.
Other factors are hinted at by the residual association with age
after using an age-adjusted measure of COPD and after pack-
years of smoking has been taken into account. These findings
re-emphasise the urgency of stopping the smoking epidemic
and the need for better understanding of the determinants of
lung health in poorer regions of the world.
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